Drug
Cavosonstat clinical trials
Also written N91115.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
9 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2019 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 1
Nivalis Therapeutics, Inc. (7) · University of North Carolina, Chapel Hill (1) · GSNOR Therapeutics, Inc. (1)
Often tested with
Tested in the same studies.
Clazakizumab (1) · Broncho-Vaxom (1) · Imatinib (1) · Rifampin (1)
Studies
Open first, then newest update. How each study uses cavosonstat is read from its arms, and is right about nine times in ten.
Testing it · 9
- PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyCompletedPhase 2University of North Carolina, Chapel HillNCT04129931Written as Cavosonstat
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)Status unknownPhase 2GSNOR Therapeutics, Inc.NCT04600778Written as Cavosonstat 5 mg
- MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)CompletedPhase 1Nivalis Therapeutics, Inc.NCT02934139Written as Cavosonstat
- Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR MutationCompletedPhase 2Nivalis Therapeutics, Inc.NCT02589236Written as Cavosonstat
- MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy SubjectsCompletedPhase 1Nivalis Therapeutics, Inc.NCT02013388Written as N91115
- Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With IvacaftorStatus unknownPhase 2Nivalis Therapeutics, Inc.NCT02724527Written as Cavosonstat
- A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult SubjectsCompletedPhase 1Nivalis Therapeutics, Inc.NCT02500667Written as N91115
- Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR MutationCompletedPhase 1Nivalis Therapeutics, Inc.NCT02275936Written as N91115
- PK Study of N91115 in Cystic Fibrosis PatientsCompletedPhase 1Nivalis Therapeutics, Inc.NCT02227888Written as N91115
Codes
What other systems call cavosonstat · ClinicalTrials.gg INT000903
- MeSH (NLM) C000626473cavosonstatOne source ClinicalTrials.gov
- UNII (FDA) O2Z8Q22ZE4CAVOSONSTATConfirmed FDA, Wikidata
- Wikidata Q27285248cavosonstatConfirmed FDA, Wikidata
- NCI Thesaurus C174782CavosonstatOne source FDA
- DrugBank DB14775One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626473 | cavosonstat | One source ClinicalTrials.gov |
| UNII (FDA) | O2Z8Q22ZE4 | CAVOSONSTAT | Confirmed FDA, Wikidata |
| Wikidata | Q27285248 | cavosonstat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C174782 | Cavosonstat | One source FDA |
| DrugBank | DB14775 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.